Evidence map›Paper›PMID 30484958›Full record

ArticleJournal of cellular and molecular medicine2019

Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.

Fernanda Marconi Roversi, Nathalia Moreno Cury, Matheus Rodrigues Lopes, Karla Priscila Ferro, João Agostinho Machado-Neto, Marisa Claudia Alvarez, Gabriela Pereira Dos Santos, Renata Giardini Rosa, Ana Leda Longhini, Adriana da Silva Santos Duarte and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Fernanda Marconi RoversiHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Nathalia Moreno CuryCentro Infantil de Investigações Hematológicas Dr. Domingos A. Boldrini, Campinas, São Paulo, Brazil.
Matheus Rodrigues LopesHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Karla Priscila FerroHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
João Agostinho Machado-NetoHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Marisa Claudia AlvarezHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Gabriela Pereira Dos SantosHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Renata Giardini RosaHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Ana Leda LonghiniHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Adriana da Silva Santos DuarteHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Fernando Vieira PericoleHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
Patricia FavaroHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.
José Andres YunesCentro Infantil de Investigações Hematológicas Dr. Domingos A. Boldrini, Campinas, São Paulo, Brazil.
Sara Teresinha Olalla SaadHematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.ORCID 0000-0003-0809-8068
Universidade Estadual de Campinas (UNICAMP) · BRCentro Infantil Boldrini · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of tumour microenvironment in neoplasm initiation and malignant evolution has been increasingly recognized. However, the bone marrow mesenchymal stromal cell (BMMSC) contribution to disease progression remains poorly explored. We previously reported that the expression of serine protease inhibitor kunitz-type2 (SPINT2/HAI-2), an inhibitor of hepatocyte growth factor (HGF) activation, is significantly lower in BMMSC from myelodysplastic syndromes (MDS) patients compared to healthy donors (HD). Thus, to investigate whether this loss of expression was due to SPINT2/HAI-2 methylation, BMMSC from MDS and de novo acute myeloid leukaemia (de novo AML) patients were treated with 5-Azacitidine (Aza), a DNA methyltransferase inhibitor. In MDS- and de novo AML-BMMSC, Aza treatment resulted in a pronounced SPINT2/HAI-2 levels up-regulation. Moreover, Aza treatment of HD-BMMSC did not improve SPINT2/HAI-2 levels. To understand the role of SPINT2/HAI-2 down-regulation in BMMSC physiology, SPINT2/HAI-2 expression was inhibited by lentivirus. SPINT2 underexpression resulted in an increased production of HGF by HS-5 stromal cells and improved survival of CD34

Indexed as

AzacitidineCell AdhesionCell Line, TumorCell SurvivalFemaleHumansIntegrin alpha2Leukemia, Myeloid, AcuteMaleMembrane GlycoproteinsMesenchymal Stem CellsMiddle AgedMyelodysplastic SyndromesNeoplastic Stem CellsTumor MicroenvironmentAzacitidineIntegrin alpha2Membrane GlycoproteinsSPINT2 protein, humande novo acute myeloid leukaemiamesenchymal stromal cellmethylationmicroenvironment nichemyelodysplastic syndromes

Identifiers

PMID30484958
PMCPMC6349149
OpenAlexW2902926495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.